Edward White
Stock Analyst at HC Wainwright & Co.
(1.92)
# 1,521
Out of 4,479 analysts
275
Total ratings
28.62%
Success rate
-6.35%
Average return
Main Sectors:
27 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TCON TRACON Pharmaceuticals | Downgrades: Neutral | n/a | $0.95 | - | 12 | Jul 1, 2024 | |
| KPTI Karyopharm Therapeutics | Maintains: Buy | $8 → $7 | $0.80 | +774.67% | 16 | Jun 28, 2024 | |
| VALN Valneva SE | Reiterates: Buy | $26 | $7.15 | +263.89% | 24 | Jun 28, 2024 | |
| DVAX Dynavax Technologies | Reiterates: Buy | $29 | $11.09 | +161.50% | 12 | Jun 28, 2024 | |
| GTHX G1 Therapeutics | Maintains: Buy | $9 → $3 | $2.48 | +21.21% | 13 | Jun 25, 2024 | |
| ACET Adicet Bio | Reiterates: Buy | $10 | $1.14 | +781.06% | 12 | Jun 24, 2024 | |
| SNDX Syndax Pharmaceuticals | Reiterates: Buy | $41 | $21.19 | +93.49% | 20 | Jun 17, 2024 | |
| SXTP 60 Degrees Pharmaceuticals | Reiterates: Neutral | n/a | $0.24 | - | 3 | Jun 6, 2024 | |
| IFRX InflaRx | Reiterates: Buy | $8 | $1.70 | +371.98% | 15 | Jun 6, 2024 | |
| GLYC GlycoMimetics | Reiterates: Neutral | n/a | $0.28 | - | 10 | Jun 4, 2024 | |
| PBYI Puma Biotechnology | Reiterates: Buy | $7 | $3.25 | +115.72% | 13 | Jun 4, 2024 | |
| CGEM Cullinan Oncology | Reiterates: Buy | $28 | $16.45 | +70.21% | 18 | Jun 3, 2024 | |
| SNSE Sensei Biotherapeutics | Reiterates: Buy | $4 | $0.62 | +545.06% | 2 | May 24, 2024 | |
| NYXH Nyxoah | Maintains: Buy | $22 → $18 | $7.03 | +156.05% | 9 | May 24, 2024 | |
| SABS SAB Biotherapeutics | Reiterates: Buy | $6 | $2.95 | +103.18% | 12 | May 21, 2024 | |
| IKT Inhibikase Therapeutics | Maintains: Buy | $27 → $23 | $1.20 | +1,816.67% | 7 | May 21, 2024 | |
| CRIS Curis | Reiterates: Buy | $26 | $6.69 | +288.47% | 10 | May 15, 2024 | |
| BOLT Bolt Biotherapeutics | Downgrades: Neutral | n/a | $0.73 | - | 9 | May 15, 2024 | |
| TGTX TG Therapeutics | Maintains: Buy | $45 → $49 | $18.01 | +172.07% | 22 | May 2, 2024 | |
| LUMO Lumos Pharma | Reiterates: Buy | $28 | $2.32 | +1,106.90% | 11 | Mar 20, 2024 | |
| INZY Inozyme Pharma | Maintains: Buy | $16 | $4.38 | +265.71% | 6 | Mar 13, 2024 | |
| CMRX Chimerix | Reiterates: Buy | $11 | $0.87 | +1,168.74% | 9 | Mar 1, 2024 | |
| ALRN Aileron Therapeutics | Maintains: Buy | $40 → $20 | $2.83 | +606.71% | 2 | Jun 30, 2022 | |
| PMCB PharmaCyte Biotech | Initiates: Neutral | n/a | $2.12 | - | 1 | Nov 8, 2021 | |
| MRSN Mersana Therapeutics | Initiates: Buy | n/a | $1.94 | - | 1 | Aug 30, 2021 | |
| IDYA IDEAYA Biosciences | Maintains: Buy | n/a | $35.07 | - | 4 | Aug 11, 2021 | |
| FATE Fate Therapeutics | Downgrades: Neutral | n/a | $3.21 | - | 2 | Mar 6, 2018 |
TRACON Pharmaceuticals
Jul 1, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.95
Upside: -
Karyopharm Therapeutics
Jun 28, 2024
Maintains: Buy
Price Target: $8 → $7
Current: $0.80
Upside: +774.67%
Valneva SE
Jun 28, 2024
Reiterates: Buy
Price Target: $26
Current: $7.15
Upside: +263.89%
Dynavax Technologies
Jun 28, 2024
Reiterates: Buy
Price Target: $29
Current: $11.09
Upside: +161.50%
G1 Therapeutics
Jun 25, 2024
Maintains: Buy
Price Target: $9 → $3
Current: $2.48
Upside: +21.21%
Adicet Bio
Jun 24, 2024
Reiterates: Buy
Price Target: $10
Current: $1.14
Upside: +781.06%
Syndax Pharmaceuticals
Jun 17, 2024
Reiterates: Buy
Price Target: $41
Current: $21.19
Upside: +93.49%
60 Degrees Pharmaceuticals
Jun 6, 2024
Reiterates: Neutral
Price Target: n/a
Current: $0.24
Upside: -
InflaRx
Jun 6, 2024
Reiterates: Buy
Price Target: $8
Current: $1.70
Upside: +371.98%
GlycoMimetics
Jun 4, 2024
Reiterates: Neutral
Price Target: n/a
Current: $0.28
Upside: -
Puma Biotechnology
Jun 4, 2024
Reiterates: Buy
Price Target: $7
Current: $3.25
Upside: +115.72%
Cullinan Oncology
Jun 3, 2024
Reiterates: Buy
Price Target: $28
Current: $16.45
Upside: +70.21%
Sensei Biotherapeutics
May 24, 2024
Reiterates: Buy
Price Target: $4
Current: $0.62
Upside: +545.06%
Nyxoah
May 24, 2024
Maintains: Buy
Price Target: $22 → $18
Current: $7.03
Upside: +156.05%
SAB Biotherapeutics
May 21, 2024
Reiterates: Buy
Price Target: $6
Current: $2.95
Upside: +103.18%
Inhibikase Therapeutics
May 21, 2024
Maintains: Buy
Price Target: $27 → $23
Current: $1.20
Upside: +1,816.67%
Curis
May 15, 2024
Reiterates: Buy
Price Target: $26
Current: $6.69
Upside: +288.47%
Bolt Biotherapeutics
May 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.73
Upside: -
TG Therapeutics
May 2, 2024
Maintains: Buy
Price Target: $45 → $49
Current: $18.01
Upside: +172.07%
Lumos Pharma
Mar 20, 2024
Reiterates: Buy
Price Target: $28
Current: $2.32
Upside: +1,106.90%
Inozyme Pharma
Mar 13, 2024
Maintains: Buy
Price Target: $16
Current: $4.38
Upside: +265.71%
Chimerix
Mar 1, 2024
Reiterates: Buy
Price Target: $11
Current: $0.87
Upside: +1,168.74%
Aileron Therapeutics
Jun 30, 2022
Maintains: Buy
Price Target: $40 → $20
Current: $2.83
Upside: +606.71%
PharmaCyte Biotech
Nov 8, 2021
Initiates: Neutral
Price Target: n/a
Current: $2.12
Upside: -
Mersana Therapeutics
Aug 30, 2021
Initiates: Buy
Price Target: n/a
Current: $1.94
Upside: -
IDEAYA Biosciences
Aug 11, 2021
Maintains: Buy
Price Target: n/a
Current: $35.07
Upside: -
Fate Therapeutics
Mar 6, 2018
Downgrades: Neutral
Price Target: n/a
Current: $3.21
Upside: -